Determination of Higher Order Structure and Hydrogen Deuterium Exchange by LC–MS - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Determination of Higher Order Structure and Hydrogen Deuterium Exchange by LC–MS
Hydrogen deuterium exchange by mass spectrometry is a powerful analytical approach that can be used to map higher order structures of proteins.


Pharmaceutical Technology
pp. s38-240

References

1. T.E. Wales et al., Anal. Chem. 80 (17), 6815–6820 (2008).

2. R.E. Iacob, J.P. Murphy, and J.R. Engen, Rapid Commun. Mass Spectrom. 22 (18), 2898–2904 (2008).

3. J. Fang et al., Int. J. Mass Spectrom. 302 (1–3), 19–25 (2011).

4. R.E. Iacob and J.R. Engen, J. Am. Soc. Mass Spectrom. 23 (6), 1003–1010 (2012).

5. W. Hui et al., J. Am. Soc. Mass Spectrom. 23 (3), 498–504 (2012).

6. Z. Zhang and D.L. Smith, Protein Sci. 2 (4), 522–531 (1993).

7. T.E. Wales and J.R. Engen, Mass. Spectrom. Rev. 25 (1), 158–170 (2006).

8. D. Houde et al., Anal. Chem. 81 (7), 5966 (2009).

9. M.J. Chalmers et al., Anal. Chem. 78 (4), 1005–1014 (2006).

10. M.M. Zhu et al., Biochemistry 42 (51), 15388–15397 (2003).

11. Waters Corporation, "Localized Conformation Analysis of Mutated Human IgG1 by HDX–MS and nanoDSC," Application Note 720004224en (2012).

12. A. Baerga-Ortiz et al., Protein Sci. 11 (6), 1300–1308 (2002).

13. D. Houde, S.A. Berkowitz, and J.R. Engen, J. Pharm. Sci. 100 (6), 2071–2086 (2011).

14. J. Ahn, et al., poster at the 9th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry (San Diego, CA, 2012).

15. S. B. Moorthy, S. Badireddy, and G.S. Anand, Int. J. Mass Spectrom. 302 (1–3), 157–166 (2011).

16. H. Xie et al., mAbs 2 (4), 1–16 (2010).

17. J. Ahn et al., J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878 (3–4), 403–408 (2010).

18. G. Pasut and F.M. Veronese, Adv. Drug Deliv. Rev. 61 (13), 1177–1188 (2009).

19. F.M. Veronese and A. Mero, BioDrugs 22 (5), 315–329 (2008).

20. R. B. Greenwald et al., Adv. Drug Deliv. Rev. 55 (22), 217–250 (2003).

21. K.R. Reddy, Ann. Pharmacother. 34 (7–8), 915–923 (2000).

22. S. Kozlowski, Testimony, Subcommittee on Technology and Innovation Committee on Science and Technology, US House of Rep., Sept. 24, 2009.

23. FDA, "FDA Issues Draft Guidance on Biosimilar Product Development," Press Release (Silver Spring, MD, Feb. 9, 2012).

24. L. Heinemann and M. Hompesch, J. of Diabetes Sci. Technol. 5 (3) 741–54 (2011).

25. S. Nakazawa et al., poster at the 60th ASMS Conference on Mass Spectrometry and Allied Topics (Vancouver, BC, 2012).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here